Pfizer Said to Have Approached Actavis About Deal

The transcript discusses the US government's efforts to prevent corporate inversions, focusing on Pfizer's attempts to acquire AstraZeneca. Despite new rules, companies like Pfizer find ways to navigate these regulations. The US faces challenges in stopping inversions without new legislation. Pfizer's previous hostile bid for AstraZeneca was unsuccessful, but they may attempt another bid after a cooling-off period, potentially influenced by the political climate post-US midterm elections.

What was the main challenge faced by the Obama administration in stopping corporate inversions?

• Absence of legislative backing

• Opposition from pharmaceutical companies

• Inadequate funding

• Lack of public support

What was the value of Pfizer's hostile bid for AstraZeneca?

• $200 billion

• $114 billion

• $63 billion

• $150 billion

How do companies like Pfizer manage to navigate around inversion rules?

• By lobbying for new laws

• Through creative accounting and legal strategies

• By merging with smaller companies

• By relocating their headquarters

What is Pfizer's current stance on acquiring AstraZeneca?

• They are no longer interested

• They prefer a friendly acquisition

• They are waiting for a price drop

• They want a hostile takeover

Why might Pfizer's bid for AstraZeneca be more politically acceptable after the US midterm elections?

• AstraZeneca's market value might decrease

• Pfizer could gain more public support

• There might be less political rhetoric

• The elections could change the legislative landscape